- Published on
KembaraXtra- Medicine – Alpha-1-Antitrypsin Deficiency
Alpha-1-antitrypsin deficiency (AATD) is an inherited genetic disorder caused by deficiency or dysfunction of the protease inhibitor alpha-1-antitrypsin (AAT). The condition most commonly results from homozygous carriage of the SERPINA1 Z allele (PI*ZZ genotype). This mutation leads to production of an abnormal AAT protein (Z-AAT) that accumulates within hepatocytes while circulating levels of functional AAT are markedly reduced. The resulting imbalance predisposes affected individuals to early-onset pulmonary emphysema, chronic obstructive pulmonary disease (COPD), and progressive liver disease, including cirrhosis and hepatocellular carcinoma.
Alpha-1-antitrypsin deficiency is underrecognized but accounts for approximately 1% to 5% of COPD cases in the United States, with an estimated prevalence of 1 in 2000 to 5000 individuals. The disorder is inherited in an autosomal codominant fashion. The normal M allele is present in about 95% of the population, while the deficient Z allele occurs in 1% to 2% and the S allele in 2% to 3%. Severe deficiency most often occurs in individuals with the ZZ genotype, while those with SZ or MZ genotypes may have partial deficiency, with increased risk of lung disease—particularly in smokers. Approximately 1 in 10 individuals of European descent carries at least one abnormal allele.
Clinical manifestations vary depending on genotype and environmental exposures. The lungs are most commonly affected, with patients developing early-onset, lower-lobe–predominant panlobular emphysema, often before age 45 and sometimes in the absence of smoking. Symptoms resemble typical COPD and include progressive dyspnea, chronic cough, and sputum production. Bronchiectasis may also be present. Smoking significantly accelerates lung damage and worsens prognosis. Liver involvement may present as neonatal cholestasis, chronic hepatitis, cirrhosis, or hepatocellular carcinoma in both children and adults. A rare dermatologic manifestation is panniculitis, characterized by painful, inflammatory subcutaneous nodules caused by unopposed proteolysis in the skin.
The pathophysiology of AATD involves loss of antiprotease protection in the lungs and toxic accumulation of mutant AAT protein in hepatocytes. In the lungs, reduced AAT levels fail to adequately inhibit neutrophil elastase, leading to destruction of alveolar elastin and development of emphysema. In the liver, disease results not from deficiency but from intracellular retention of misfolded Z-AAT, which triggers hepatocellular injury, inflammation, and fibrosis. Not all individuals with AAT deficiency develop clinical disease, but smoking is the strongest modifiable risk factor for lung involvement.
Diagnosis should be suspected in patients with early-onset COPD, emphysema without typical risk factors, or basilar-predominant emphysema on imaging. Unexplained liver disease, panniculitis, bronchiectasis, poorly responsive asthma, or c-ANCA–associated vasculitis should also prompt evaluation. Initial testing includes measurement of serum alpha-1-antitrypsin levels, followed by genotyping to identify specific alleles. Pulmonary function testing typically shows airflow obstruction consistent with COPD. Imaging with chest radiography or high-resolution computed tomography often demonstrates lower-lobe–predominant emphysema and may reveal bronchiectasis.
Management begins with nonpharmacologic interventions, most importantly complete avoidance of smoking, which dramatically reduces the risk and progression of lung disease. Patients should also avoid occupational and environmental exposures that damage the lungs and receive routine vaccinations, including influenza, pneumococcal, pertussis, and SARS-CoV-2 vaccines. Acute COPD exacerbations are treated similarly to those in patients without AATD.
For chronic management, the therapeutic goal is to raise serum AAT levels above the protective threshold of approximately 50 mg/dL. Currently, the only FDA-approved disease-specific therapy is intravenous alpha-1-antitrypsin augmentation therapy, which uses pooled human AAT to slow progression of emphysema. This treatment requires lifelong administration, is costly, and does not reverse established lung damage nor improve liver disease. Patients with end-stage lung or liver disease may be candidates for organ transplantation, which can be life-saving and curative for the affected organ.
Prognosis depends on genotype, degree of deficiency, and environmental factors. Among patients with severe AATD, respiratory failure is the leading cause of death, followed by cirrhosis and liver-related complications. Early diagnosis, smoking cessation, and appropriate specialty care significantly improve outcomes. Referral to clinicians experienced in managing AATD is recommended, including pulmonology, hepatology, and transplant centers when indicated.
Alpha-1-antitrypsin deficiency remains substantially underdiagnosed, and expert guidelines recommend testing all patients with COPD, emphysema, irreversible asthma, unexplained liver disease, bronchiectasis, or panniculitis, as well as first-degree relatives of affected individuals. Early recognition allows for risk reduction, appropriate monitoring, and timely intervention to prevent irreversible organ damage.
- Published on
KembaraXtra-Medicine – Amaurosis Fugax
Amaurosis fugax is defined as a transient loss of monocular vision caused by temporary retinal ischemia resulting from a reversible occlusion of the ophthalmic artery or its branches. The ophthalmic artery arises from the internal carotid artery, and the central retinal artery is a branch of the ophthalmic artery. This condition is classified under ICD-10CM code G45.3 and is considered an important warning sign of underlying vascular disease.
From an epidemiologic perspective, amaurosis fugax is an uncommon but clinically significant presentation of carotid artery disease in the United States. The peak incidence occurs around 55 years of age, and its recognition is critical because it often represents a form of transient ischemic attack (TIA) with potential risk for future stroke.
The clinical presentation is typically sudden in onset and lasts seconds to minutes. Patients often describe the vision loss as a shade or curtain descending over the eye, most commonly from above downward. The visual deficit may be complete or partial and can involve hemianopic or quadrantic vision loss. During the acute stage, cholesterol emboli, known as Hollenhorst plaques, may sometimes be visualized within the retinal arteries on funduscopic examination.
The etiology of amaurosis fugax is most often embolic in nature. Emboli may originate from the internal carotid artery, usually in the setting of carotid atherosclerotic stenosis, or from the heart, with atrial fibrillation being the most common cardiac source. Carotid artery emboli are typically identified as stenosis on carotid imaging such as CT angiography, MR angiography, or carotid ultrasound. Other important causes include giant cell arteritis, which produces inflammatory occlusion of retinal arteries; hyperviscosity syndromes such as sickle cell disease; hypercoagulable states; and reversible cerebral vasoconstriction syndrome.
In terms of differential diagnosis, retinal migraine must be considered, as it differs by having a gradual onset of visual symptoms over 15 to 20 minutes rather than sudden loss. Transient visual obscurations associated with papilledema also differ, as they are typically brief (1–2 seconds), may be binocular, and are related to transient increases in intracranial pressure. If vision loss persists at the time of evaluation, the differential should be expanded to include arteritic or nonarteritic anterior ischemic optic neuropathy, central retinal artery occlusion, and branch retinal artery occlusion.
The diagnostic workup should prioritize identifying embolic sources, while giant cell arteritis must always be considered, particularly in older adults. A careful retinal examination may reveal an embolus, which can confirm the diagnosis. Auscultation for carotid bruits, examination of peripheral pulses, and assessment for temporal artery tenderness are essential. Patients should be questioned about symptoms suggestive of giant cell arteritis, including headache, scalp tenderness, fever, and jaw claudication. A focused neurologic examination is necessary to evaluate for signs of hemispheric stroke, such as contralateral weakness, sensory loss, or aphasia.
Laboratory evaluation includes a complete blood count along with erythrocyte sedimentation rate and C-reactive protein to assess for inflammation, particularly when giant cell arteritis is suspected. Additional studies include serum chemistries, lipid profile, hemoglobin A1C, cardiac enzymes, and electrocardiography. A hypercoagulable workup may be pursued selectively in younger patients or when the history suggests an underlying thrombophilic disorder.
Imaging studies are central to evaluation. CT or MR angiography of the head and neck is preferred to assess carotid and intracranial vasculature, with carotid ultrasound as an alternative when angiography is contraindicated. MRI of the brain with diffusion-weighted imaging is recommended to identify silent or symptomatic infarcts. Transthoracic echocardiography is used to screen for cardiac embolic sources, while transesophageal echocardiography provides greater sensitivity for detecting left atrial appendage thrombi, patent foramen ovale, ventricular mural thrombus, or aortic arch atheroma. Extended cardiac rhythm monitoring is advised when neither carotid disease nor giant cell arteritis explains the presentation.
Management begins with nonpharmacologic therapy, including dietary modification to reduce saturated fats and cholesterol, regular exercise, and cessation of tobacco and illicit drug use. These measures address the underlying vascular risk factors that contribute to embolic disease.
From an acute management standpoint, amaurosis fugax should be treated as a medical emergency, similar to other forms of TIA. Aspirin therapy should be initiated promptly. If giant cell arteritis is suspected, high-dose prednisone must be started immediately, and the patient should be referred urgently for temporal artery biopsy within 48 hours.
Chronic management focuses on secondary stroke prevention. Carotid endarterectomy is recommended for patients with carotid stenosis greater than 50%, and carotid stenting may be considered in patients who are poor surgical candidates. Aggressive management of vascular risk factors—including hypertension, hyperlipidemia with statin therapy, diabetes, and smoking cessation—is essential. Antiplatelet therapy is indicated for atherosclerotic disease or following carotid intervention, while anticoagulation is required when atrial fibrillation is identified as the etiology.
Regarding prognosis, patients with greater than 50% carotid stenosis who do not undergo carotid endarterectomy and present with transient monocular blindness have an estimated 10% risk of stroke within 3 years, compared with approximately 20% risk in those presenting with hemispheric TIA.
Appropriate referral is critical. As with any TIA, patients should undergo emergent inpatient evaluation at a certified stroke center whenever possible. Carotid endarterectomy or stenting should be considered in patients with ipsilateral high-grade stenosis (≥70%), and may also be appropriate for stenosis of 50%–69% or in patients experiencing multiple TIAs despite optimal medical therapy.
Key clinical pearls include recognizing that visualization of cholesterol emboli in retinal arteries on fundoscopy confirms the diagnosis, understanding that transient visual loss has multiple potential causes, and ensuring that amaurosis fugax is managed with the same urgency as other transient ischemic attacks.
- Published on
KembaraXtra-Medicine – Alzheimer Disease
Dementia is a syndrome characterized by progressive loss of previously acquired cognitive skills, including memory, language, insight, and judgment. Alzheimer disease (AD) is thought to account for the majority of all cases of dementia. The ICD-10CM codes for Alzheimer disease include G30.0 (Alzheimer disease with early onset), G30.1 (Alzheimer disease with late onset), G30.8 (other Alzheimer disease), and G30.9 (Alzheimer disease, unspecified).
The incidence of Alzheimer disease increases markedly with age, with risk doubling every 5 years after age 65. The Chicago Health and Aging Population study demonstrated an average annual incidence of 2.3% among individuals aged 65 years and older, with Black individuals having a significantly increased risk compared with White individuals. In terms of prevalence, approximately 1 in 9 people (10.7%) aged 65 years or older has Alzheimer dementia. In the United States, an estimated 6.5 million people are affected, including 5% of individuals aged 65–74 years, 13.1% of those aged 75–84 years, and 33.2% of those aged 85 years or older. Additionally, 12%–18% of adults over age 60 are believed to have mild cognitive impairment (MCI). Alzheimer disease affects women more frequently than men, with approximately 4 million women and 2.5 million men affected nationwide.
Clinically, Alzheimer disease most often presents insidiously. A spouse or close family member usually first notices progressive memory impairment rather than the patient. Individuals have difficulty learning and retaining new information, managing complex tasks such as finances, and demonstrate impairments in judgment, reasoning, visuospatial abilities, and orientation, often leading to problems such as getting lost or difficulty driving. Behavioral and personality changes, including apathy and mood disturbances, commonly accompany memory loss, and later stages may involve agitation, delusions, or psychosis. Rare atypical variants include early and severe behavioral changes, focal neurologic findings, parkinsonism, hallucinations, frequent falls, or onset of symptoms at or before 65 years of age.
The diagnosis of Alzheimer disease has evolved with the development of biomarkers that demonstrate Alzheimer pathology in vivo, particularly amyloid beta deposition and pathologic tau accumulation. The National Institute on Aging–Alzheimer’s Association (NIA-AA) criteria, initially published in 2011 and revised in 2018, conceptualize Alzheimer disease as a biologic process rather than solely a clinical syndrome. These criteria define three stages: preclinical Alzheimer disease (biologic evidence without symptoms), MCI due to Alzheimer disease (mild memory impairment without functional decline but with biomarker evidence), and dementia due to Alzheimer disease (cognitive decline with functional impairment and biomarker confirmation). The 2018 framework further introduced the ATN system, defining disease by amyloid (A), tau pathology (T), and neurodegeneration (N). Although biomarkers are not yet routinely used in general clinical practice, they are integral to research and clinical trials.
In routine clinical settings, Alzheimer disease is typically diagnosed using clinical history, neurologic examination, and established criteria such as DSM-5 or NINCDS-ADRDA. Core features include progressive memory loss plus at least one additional cognitive deficit (aphasia, apraxia, agnosia, or executive dysfunction), decline in social or occupational functioning, insidious onset with gradual progression, objective documentation of cognitive loss, and exclusion of alternative causes. Red flags suggesting an alternative diagnosis include age younger than 65 years, fluctuating consciousness, rapid progression over months, prominent early behavioral changes, or focal neurologic findings such as gait disturbance, lateralized weakness, myoclonus, or parkinsonism.
The differential diagnosis of Alzheimer disease is broad and includes other neurodegenerative dementias such as frontotemporal lobar degeneration, dementia with Lewy bodies, Parkinson disease dementia, corticobasal syndrome, progressive supranuclear palsy, limbic-predominant age-related TDP-43 encephalopathy, and primary age-related tauopathy. Nondegenerative conditions include vascular cognitive impairment, depression (pseudodementia), subjective memory complaints, brain tumors, chronic subdural hematoma, infections such as HIV or neurosyphilis, toxic or metabolic encephalopathies, and organ failure–related cognitive impairment.
Evaluation begins with a comprehensive history and physical examination, including careful medication review to identify agents that impair cognition, such as anticholinergics, benzodiazepines, opioids, barbiturates, and neuroleptics. Screening for depression is essential, as it may mimic or coexist with dementia. Cognitive screening tools such as the Mini-Mental State Examination, Mini-Cog, and Montreal Cognitive Assessment are commonly used, while formal neuropsychologic testing is reserved for atypical cases or diagnostic uncertainty. In Alzheimer disease, episodic memory deficits typically appear early, whereas attention is often preserved until later stages.
Laboratory evaluation usually includes complete blood count, serum electrolytes, glucose, renal and liver function tests, thyroid function tests, and vitamin B12 levels, with additional testing guided by clinical context. Neuroimaging, preferably MRI, is used to exclude alternative diagnoses and assess characteristic patterns of neurodegeneration, such as hippocampal atrophy. Amyloid and tau PET imaging may support diagnosis in selected cases but are not diagnostic on their own.
Management of Alzheimer disease incorporates both nonpharmacologic and pharmacologic strategies. Nonpharmacologic care focuses on patient safety, caregiver education, behavioral interventions, and cognitive stimulation. Addressing driving safety, wandering, medication management, and household hazards is essential. Behavioral symptoms such as agitation, repetitive questioning, and social withdrawal often respond to structured routines and environmental modifications. A person-centered, interdisciplinary approach tailored to disease stage improves quality of life for both patients and caregivers.
Pharmacologic treatment is primarily symptomatic. Cholinesterase inhibitors (donepezil, rivastigmine, and galantamine) are approved for mild to moderate Alzheimer disease, with donepezil also approved for severe disease. These agents provide modest cognitive and functional benefits but may cause gastrointestinal effects, bradycardia, and sleep disturbances. Memantine, an NMDA receptor antagonist, is approved for moderate to severe Alzheimer disease. Newer anti-amyloid monoclonal antibodies, such as aducanumab and lecanemab, target amyloid pathology and may modestly slow cognitive decline in early disease but require careful patient selection and monitoring due to safety concerns.
Patients with atypical presentations or complex management needs should be referred to specialists with expertise in dementia care. Ongoing caregiver education and support are critical, as they reduce caregiver burden, delay institutionalization, and improve patient outcomes. Prevention strategies emphasize physical activity, cardiovascular risk factor control, cognitive engagement, healthy diet patterns, and avoidance of tobacco and excessive alcohol use.
- Published on
KembaraXtra-Medicine – Anal Fissure
An anal fissure is a tear in the epithelial lining of the anal canal, extending from the dentate line to the anal verge. Acute anal fissures usually heal with conservative treatment within 6 weeks, while chronic fissures typically need a more aggressive approach and may require surgery. Synonyms include anorectal fissure and anal ulcer. The ICD-10CM codes are K60.0 (acute anal fissure), K60.1 (chronic anal fissure), and K60.2 (anal fissure, unspecified).
An estimated 235,000 new cases occur each year in the United States. Anal fissures can happen at any age but are more common in infants and middle-aged adults, and they occur more often in men than women. Women are more likely than men to have an anterior fissure (10% vs 1%, respectively).
Clinically, separating the buttocks typically reveals a tear in the posterior midline or less often the anterior midline. Acute fissures usually cause sharp burning or tearing pain with bowel movements and may produce bright-red blood on toilet paper, as a streak on stool, or in the toilet water; they look like a fresh laceration. Chronic fissures are more associated with perianal pruritus or irritation, less intense pain or no pain, and intermittent bleeding. They may show a sentinel tag at the caudal aspect, a hypertrophied anal papilla proximally, and raised edges that expose the horizontal fibers of the internal anal sphincter, reflecting chronic infection and fibrosis. Atypical fissures (acute or chronic) are more likely to appear off the midline, may extend proximal to the dentate line, may be unusually wide or deep, and may be multiple, recurring, or nonhealing; they can be associated with an edematous, tender perianal tag and are more often linked to an underlying systemic disease.
Most fissures start after passing a large, hard stool, but they can also result from frequent defecation and diarrhea. Infectious causes include bacterial infections such as tuberculosis, syphilis, gonorrhea, chancroid, and lymphogranuloma venereum, and viral infections such as herpes simplex virus, cytomegalovirus, and HIV. Other causes include inflammatory bowel disease (Crohn disease, ulcerative colitis), trauma (e.g., hemorrhoidectomy, foreign bodies, anal intercourse), and malignancy (carcinoma, lymphoma, Kaposi sarcoma).
Important differential diagnoses include proctalgia fugax, thrombosed hemorrhoid, carcinoma, and anal fistula. Evaluation may include a digital rectal examination performed only after fully lubricating the anus with 2% lidocaine jelly and waiting 5–10 minutes, plus anoscopy and proctosigmoidoscopy to exclude inflammatory or neoplastic disease. A biopsy is recommended if there is doubt about the cause, and studies should be done with adequate anesthesia. Colonoscopy is considered if IBD or malignancy is suspected, and a small-bowel series is occasionally obtained for similar reasons.
Nonpharmacologic management includes sitz baths, a high-fiber diet, and increased oral fluids. Acute treatment includes a bulk-forming agent (e.g., Metamucil) and/or a stool softener, and local anesthetic jelly (though it may worsen pruritus ani). Nitroglycerin ointment 0.4% can be used by applying 1 inch of ointment (≈1.5 mg nitroglycerin) intra-anally every 12 hours for up to 3 weeks; this product (Rectiv) can be expensive, and topical diltiazem (pharmacy-compounded) is also effective and usually cheaper. Suppositories are not recommended. If medical therapy fails after 2 months, surgery is considered.
For chronic fissures, medical therapy may still be offered because it is often better tolerated and avoids the risk of fecal incontinence. Options include topical glyceryl trinitrate, topical calcium channel blockers (e.g., topical nifedipine or topical 2% diltiazem cream), and botulinum toxin A injections into each side of the internal anal sphincter; botulinum toxin can heal chronic fissures in more than 90% of patients, although dosing and best injection site are not fully clear and it can be expensive. The standard, durable surgical treatment is lateral internal anal sphincterotomy, which has >90% long-term healing, is generally durable, and is noted not to compromise long-term fecal continence in the provided text—though it can lead to fecal incontinence and therefore requires careful patient selection.
Disposition is typically outpatient surgery when surgery is needed. Referral is recommended if the fissure does not improve with conservative measures in 4–6 weeks, if the patient prefers surgery for an acute fissure, or if the patient has a chronic fissure. A special consideration is that HIV-positive patients should be referred to clinicians experienced with the infectious and neoplastic conditions that can mimic anal ulcers in this population.
- Published on
KembaraXtra-Medicine – Anal Cancer
Anal cancer refers to malignant transformation of the mucosa within the anal canal and may be squamous, neuroendocrine, or adenocarcinoma in subtype. It is also known as anal carcinoma, cancer of the anal canal, or malignant neoplasm of anus. The ICD-10CM code listed is C21.1 (Malignant neoplasm of anal canal).
Anal cancer is uncommon, occurring at a rate of 1–2 new cases per 100,000 population, with a median age of 63 years; in HIV-infected patients, the median age is <50 years. in the united states, 2022 estimates projected 9440 new cases and 1670 deaths. worldwide, 2020 (globocan) 50,865 19,293 deaths from anal cancer. incidence has increased 2%–3% annually over last 3 decades u.s., including young black men older women. there also been an increase locally advanced (node-positive) distant-disease cases, along with mortality elderly patients.< />pan>
The rise in incidence has been noted alongside the HIV epidemic and increased rates of sexually transmitted diseases. Risk factors include HIV infection (and unlike other HIV-associated malignancies, anal cancer incidence has not decreased in the era of highly active antiretroviral therapy), human papillomavirus (HPV) infection, cigarette smoking, and sexual practice risks such as men who have sex with men (MSM), women with >10 partners, and a history of anal intercourse. Additional risks include prior sexually transmitted diseases, genital warts, prior cervical cancer, and chronic immunosuppression.
Clinical presentation is often related to tumor size and degree of infiltration. Anorectal bleeding is the most common symptom, and patients may also report anorectal pain and fullness, as well as bowel habit changes including thin-caliber stools and a sense of incomplete evacuation. However, 20%–25% of patients may be asymptomatic. Local examination may reveal skin lesions, plaques, tumors, and a background of warts. Digital rectal examination assesses sphincter function, tumor location and size, tumor extent, and possible involvement of adjacent organs (e.g., vagina, prostate, rectum). At diagnosis, most cases are localized (85%), while the remainder are advanced or metastatic; inguinal adenopathy may be present in advanced disease.
Anal cancer development is strongly linked to anogenital HPV infection, especially HPV-16 and HPV-18, which account for most cases. Most infected individuals remain asymptomatic, and only some develop dysplasia over time. HPV proteins E6 and E7 promote oncogenesis by preventing apoptosis, causing cell-cycle arrest, and contributing to genomic instability. Chronic immunosuppression (e.g., from autoimmune therapy or organ transplantation) increases genital warts and persistence of HPV infection, promoting anal intraepithelial neoplasia (AIN) and eventual cancer. In HIV infection, low CD4 counts are a risk factor for development and progression of AIN.
The differential diagnosis includes anal fissures and fistulas, anal ulcers, anorectal abscess, chancroid, genital warts, and hemorrhoids.
Workup begins with careful local assessment: local examination followed by anoscopy/proctoscopy and colonoscopy to evaluate tumor extent. Imaging includes CT scans of the chest, abdomen, and pelvis to assess nodal and distant disease; pelvic MRI for tumor detail, sphincter involvement, and mesorectal nodal evaluation; and PET scans to detect nodal involvement and to help monitor response to therapy. Biopsy of the anal lesion is required to confirm diagnosis and cancer type, and inguinal nodal biopsy may be necessary to determine metastatic involvement. Recommended diagnostic evaluation includes digital rectal examination with tumor characterization, inguinal lymph node examination with biopsy or fine-needle aspiration if suspicious, anoscopy with biopsy, and in females a gynecologic examination including cervical cancer screening. Additional evaluation includes diagnostic PET-CT of chest/abdomen/pelvis (or pelvic MRI), CBC with serum chemistries, and HIV testing with CD4 levels in patients with risk factors. Laboratory tests include CBC, a complete metabolic panel, and HIV testing.
Staging uses TNM descriptors. T categories include Tx (cannot be assessed), T0 (no evidence), Tis (carcinoma in situ--Bowen disease/HSIL/AIN II-III), T1 (≤2 cm), T2 (>2 cm to ≤5 cm), T3 (>5 cm), and T4 (any size invading adjacent organ[s]); invasion of the rectal wall, perirectal skin, subcutaneous tissue, or sphincter muscles is not classified as T4. N categories include Nx (cannot be assessed), N0 (no regional metastasis), N1 (perirectal nodes), N2 (unilateral internal iliac and/or inguinal nodes), and N3 (perirectal and inguinal nodes and/or bilateral internal iliac and/or inguinal nodes). M categories are M0 (no distant metastasis) and M1 (distant metastasis). Stage groupings are: Stage 0 (Tis N0 M0), Stage I (T1 N0 M0), Stage II (T2–T3 N0 M0), Stage IIIA (T1–T3 N1 M0 or T4 N0 M0), Stage IIIB (T4 N1 M0 or any T with N2/N3 M0), and Stage IV (any T, any N, M1).
For most anal cancers, the mainstay of therapy is nonsurgical, using radiotherapy concurrent with systemic chemotherapy. Early small tumors (T1N0)—especially on the anal margin—may be treated with local surgical resection with wide margins. In some patients, a temporary colostomy may be needed to facilitate chemoradiotherapy. Abdominoperineal resection (APR) is generally reserved as salvage for persistent disease after definitive chemoradiotherapy or for locoregional recurrence.
Historically, APR achieved surgical cures in 25%–75%, but had up to a 35% locoregional relapse rate, especially with nodal involvement. Current standard care is mitomycin plus infusional 5-fluorouracil given concurrently with pelvic radiotherapy over about 5 weeks (CRT). If response is incomplete and biopsies remain positive, options include a radiotherapy boost or salvage APR. Combined-modality CRT is superior to radiotherapy alone and improves locoregional control, progression-free survival, overall survival, and colostomy-free survival. Major toxicities include myelosuppression, infections, dermatologic toxicity, and GI toxicity. Current clinical trials are studying radiotherapy de-escalation within CRT to reduce toxicity and improve tolerability and compliance. Locoregional recurrence occurs in about 10%–30%, and 5-year survival after salvage APR is about 40%–60%.
For distant metastatic or nonsurgical advanced disease, combination chemotherapy is preferred. Triplet regimens such as docetaxel/cisplatin/5-fluorouracil (DCF) may be used in fit patients, with >80% response rates and ~25% 5-year survival. Doublets such as CF (cisplatin/5-FU) or CP (carboplatin/paclitaxel) have response rates around 60% and median overall survival ~2 years; due to favorable toxicity, CP is preferred. In chemotherapy-refractory advanced disease, options include immune checkpoint inhibitors (nivolumab, pembrolizumab, avelumab, atezolizumab), and cetuximab (anti-EGFR) may be used palliatively.
Long-term care may include colostomy care and attention to nutritional requirements. Ongoing regular follow-up and examination are recommended to detect locoregional or distant recurrence. Referral is typically made to surgical oncology, radiation oncology, and medical oncology.
No formal screening guideline exists, but high-risk individuals (e.g., chronic immunosuppression, HIV, MSM) should be considered for routine local exam with anoscopy every 4–6 months plus annual anal cytology. Prevention is expected to be influenced by HPV vaccination. Gardasil 9 protects against nine HPV subtypes. Recommendations include vaccination for all children ages 11–12, girls/women ages 13–26, boys/men ages 13–21, and high-risk men ages 22–26, with an expanded indication allowing ages 27–45 to receive catch-up vaccination. In a randomized trial of 4459 participants with biopsy-proven HSIL, active treatment (office-based ablation, ablation/excision under anesthesia, or topical fluorouracil or imiquimod) continued until HSIL resolved, with high-resolution anoscopy at least every 6 months and biopsies per protocol. Over a median follow-up of 25.8 months, progression to anal cancer was 57% lower in the treatment group than in the active-monitoring group.
- Published on
KembaraXtra-Medicine – Anaerobic Infections
Anaerobic infection is caused by bacteria that require a reduced oxygen tension for growth. Relevant ICD-10CM codes include A41.4 (Sepsis, anaerobic) and A48 (Cellulitis, anaerobic).
Anaerobic infections may occur at any site, but most are anatomically related to mucosal surfaces. They should be suspected when there is foul-smelling tissue, soft tissue gas, necrotic tissue, or abscess formation. In the head and neck, odontogenic infections from dental or soft tissue sources may progress to periapical abscesses and sometimes extend to bone. Chronic sinusitis, chronic mastoiditis, peritonsillar abscess, and chronic otitis media can involve both anaerobic and aerobic pathogens. Complications include deep neck space infections, brain abscesses, and mediastinitis. Specific head and neck examples include Ludwig angina, a bilateral infection of the sublingual and submandibular spaces causing swelling at the base of the tongue with potential airway compromise and usually involving mixed aerobic/anaerobic flora, and Lemierre syndrome, a jugular vein suppurative thrombophlebitis caused by anaerobic bacteria, classically Fusobacterium necrophorum.
In pleuropulmonary disease, infection may involve anaerobes that normally reside in the oropharynx. Aspiration is more common in people with altered mental status or seizures, and anaerobic infection is more likely in those with gingivitis or periodontitis. Manifestations include necrotizing pneumonia, empyema, and lung abscess. In intraabdominal infections, disruption of intestinal integrity can lead to anaerobic infection; bacteria may originate from colonic neoplasm, perforated appendicitis, diverticulitis, or bowel surgery, resulting in bacteremia, peritonitis, and sometimes intraabdominal abscesses. These infections are usually mixed, containing both anaerobes and aerobes. In the female genital tract, anaerobes are involved in bacterial vaginosis, salpingitis, endometritis, pelvic abscesses, and septic abortion, and these infections also tend to be mixed. Pelvic thrombophlebitis may occur when a resolving pelvic infection is accompanied by new or persistent fever.
Other anaerobic infections include skin and soft tissue infections at any site, with more commonly associated entities such as synergistic gangrene, bite wound infections, and infected decubitus ulcers. The clinical significance of anaerobes in diabetic foot infections is unclear. Anaerobic bacteremia is not common; when it occurs the source is most often intraabdominal, followed by female genital tract, pleuropulmonary, and head/neck sources. Anaerobes can also be involved in osteomyelitis, especially when associated with decubitus ulcers or vascular insufficiency, and facial bone osteomyelitis can arise from adjacent infections of teeth or sinuses.
Etiologically, anaerobic infections are most commonly endogenous, arising from bacteria that normally line mucosal surfaces. Infection results when mucosal barriers are disrupted by trauma, ischemia, surgery, or perforation, allowing organisms access to normally sterile sites, causing tissue destruction and abscess formation. Synergy between different anaerobes, or between anaerobes and aerobes, is important. Examples of anaerobic bacteria include gram-negative organisms such as Bacteroides spp., Fusobacterium, and Prevotella spp., and gram-positive organisms such as Peptostreptococcus, Clostridioides spp., Finegoldia magna, and Actinomyces spp.
The main differential diagnosis is an aerobic bacterial infection without anaerobes. Another key differential is ischemic necrosis without infection, distinguishing “dry” gangrene (noninfected necrosis) from “wet” gangrene (infected tissue with anaerobic infection).
Workup requires attention to specimen handling: samples submitted for anaerobic culture should be processed within 30 minutes, and growth may take 5–7 days. A large volume of material is more likely to yield significant growth; swabs are less efficient for transporting infected material. Blood cultures should be obtained, preferably before antibiotics are given. Laboratory findings may include elevated WBC count (extremely high counts can be seen with pseudomembranous colitis), positive stool C. difficile testing by PCR/NAAT, increased lactate levels in ischemia or perforation, and possible positive blood or wound cultures—though failure to grow anaerobes is common due to inadequate culturing techniques or fastidious organisms. Imaging may include plain films to show gas in tissues, free air from perforated viscus, or air/fluid levels within an abscess, and ultrasound/CT/MRI to identify abscesses or tissue destruction.
Treatment includes nonpharmacologic measures such as removal of necrotic tissue and drainage of abscesses, often accomplished via CT-guided percutaneous drainage. Oral antibiotic options with anaerobic activity include clindamycin, metronidazole, and chloramphenicol, with broader coverage from amoxicillin/clavulanate; penicillin VK is used for odontogenic infections. For C. difficile–associated diarrhea, oral vancomycin is now the preferred agent, while metronidazole is considered second-line; oral vancomycin is used for subsequent episodes and for pulse or taper regimens. For more serious illness, parenteral options include IV clindamycin, metronidazole, and chloramphenicol; cephalosporins with anaerobic or mixed coverage such as cefoxitin and cefotetan; extended-spectrum penicillins (e.g., piperacillin) and beta-lactam/beta-lactamase inhibitor combinations with significant anaerobic activity and varying broad-spectrum coverage, including ampicillin/sulbactam, ticarcillin/clavulanate, and piperacillin/tazobactam; and carbapenems such as imipenem, meropenem, doripenem, or ertapenem, which have extensive anaerobic activity. Actinomycosis is treated with penicillin for 6–12 months. Sulfamethoxazole-trimethoprim and fluoroquinolones are generally ineffective, though some newer quinolones such as moxifloxacin have inhibitory activity against anaerobes.
Disposition emphasizes that all necrotic debris must be removed or the infection will recur, and follow-up is critically important to ensure resolution. Referral to a surgeon is appropriate if drainage is required, and infectious disease consultation may be helpful in complicated patients or when the regimen is failing or response is slow. Resistance rates are generally low for many agents used against anaerobes (reported rates: piperacillin/tazobactam 0.5%, ampicillin/sulbactam 3%), though one study found >50% resistance of Bacteroides fragilis to clindamycin.
- Published on
KembaraXtra-Medicine – Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic lateral sclerosis (ALS) is a progressive and fatal degenerative neuromuscular condition of undetermined etiology that affects the corticospinal tracts and anterior horn cells, resulting in dysfunction of both upper motor neurons (UMNs) and lower motor neurons (LMNs). Synonyms include Lou Gehrig disease, ALS, and motor neuron disease. The ICD-10CM code is G12.21 (Amyotrophic lateral sclerosis).
ALS incidence is about two new cases per 100,000 persons per year. Onset is usually between 50 and 70 years, and the male-to-female ratio is 1.8:1. The estimated prevalence is 5.2 per 100,000 population.
Clinical presentation typically includes a combination of LMN signs—weakness, hypotonia, muscle wasting, fasciculations, and hyporeflexia or areflexia—and UMN signs—loss of fine motor dexterity, spasticity, extensor plantar responses, hyperreflexia, and clonus. Extraocular movements, sensation, and bowel and bladder function are typically preserved. Patients may develop dysarthria, dysphagia, pseudobulbar affect, and frontal lobe dysfunction. Respiratory insufficiency progresses to respiratory failure and death, typically late in the disease. Concomitant frontotemporal dementia occurs in about 15%, and executive dysfunction occurs in another 50%. Pseudobulbar affect (inappropriate crying or laughing not triggered by typical emotional cues) is common and treatable.
ALS commonly manifests in one of three onset patterns. Limb onset accounts for 75%–80% of cases and presents with painless muscle weakness, clumsiness (dropping things, stumbling, falling), impaired fine motor skills (e.g., writing), limb stiffness, gait disturbances, and wristdrop or footdrop. Bulbar onset accounts for 20%–25% and presents with dysarthria or voice change, pseudobulbar affect, dysphagia and/or weight loss, drooling, and choking during swallowing. Respiratory onset occurs in <3% and presents with dyspnea on exertion or at rest, orthopnea, daytime sleepiness, difficulty sleeping, other symptoms of respiratory compromise. als makes up about 90% adult-onset motor neuron diseases; disease presentations include progressive muscular atrophy, primary lateral sclerosis, bulbar palsy, pseudobulbar als-parkinsonism-dementia complex.< />pan>
Regarding etiology and classification, 90% of cases are sporadic and 10% are familial. Known genetic mutations include C9orf72 hexanucleotide repeat expansion (responsible for ~40% of familial ALS among those of European origin and nearly 10% of sporadic ALS, and virtually all ALS cases associated with frontotemporal dementia), SOD1 (copper-zinc superoxide dismutase) mutations (~12% of familial cases), TAR DNA-binding protein mutations (~4% of familial cases), and FUS (~4% of familial cases, rarely associated with frontotemporal dementia), among many others. Risk is increased in Whites, non-Hispanics, age >60 years, family history of ALS, and prior exposure to heavy metals, pesticides, or BMAA. A practical classification includes sporadic/acquired ALS variants (classic spinal-onset, Mills hemiplegic variant, pseudoneuritic, flail-arm, monomelic, UMN onset, LMN onset, bulbar onset, dyspnea onset, progressive muscular atrophy, primary lateral sclerosis, progressive bulbar palsy, Western Pacific ALS) and multiple familial ALS subtypes (ALS1 through ALS25 and additional rare-mutation forms). An FTD-ALS overlap is also recognized (e.g., ALS-FTD associated with C9orf72; and FTD with some ALS features associated with tau and progranulin genes on chromosome 17).
The differential diagnosis includes multifocal motor neuropathy with conduction block; cervical spondylotic myelopathy with polyradiculopathy; spinal stenosis with lumbosacral nerve root compression; chronic inflammatory demyelinating polyneuropathy with CNS lesions; syringomyelia; syringobulbia; foramen magnum tumor; meningeal carcinomatosis; spinal muscular atrophy; polyglucosan body disease; bulbospinal muscular atrophy (Kennedy disease); monomelic amyotrophy; Lyme disease; and ALS-like syndromes reported with lead intoxication, HIV, hyperparathyroidism, hyperthyroidism, lymphoma, and vitamin B12 deficiency.
Diagnosis is based on clinical findings, electromyography results, and exclusion of alternative causes. Workup includes MRI of brain and spine to exclude mimics; electromyography and nerve conduction studies following Revised El Escorial criteria; assessment of respiratory function (forced vital capacity [FVC], negative inspiratory force); assessment of swallowing and nutritional status; and neuropsychologic testing if executive dysfunction or FTD is a concern. The Revised El Escorial criteria require evidence of LMN degeneration (clinical, electrophysiologic, or neuropathologic), evidence of UMN degeneration (clinical), and progressive spread of symptoms/signs within or between regions, together with absence of electrophysiologic/pathologic evidence of another disease explaining UMN/LMN degeneration and absence of neuroimaging evidence of another explanatory disease process. Levels of certainty include Definite ALS (UMN and LMN signs in three regions), Probable ALS (UMN and LMN signs in two regions with UMN signs rostral to LMN signs), Probable ALS—Laboratory Supported (UMN signs in one or more regions with LMN signs by EMG in at least two regions), and Possible ALS (UMN and LMN signs in one region together, or UMN signs in two or more regions, or UMN and LMN signs in two regions without UMN signs rostral to LMN signs).
Laboratory tests that may be considered include vitamin B12, thyroid function, parathyroid hormone, and HIV, plus serum protein electrophoresis with immunofixation. In pure LMN syndromes, consider DNA studies for spinal muscular atrophy, bulbospinal atrophy (Kennedy disease), and hexosaminidase levels (late-onset Tay-Sachs). A 24-hour urine heavy metal screen may be done if indicated. In familial ALS, genetic studies should be performed with appropriate genetic counseling. Imaging is guided by clinical scenario; MRI brain and spinal cord help exclude structural mimics, and a modified barium swallow evaluates aspiration risk.
Treatment includes symptomatic management plus disease-modifying therapy that slows progression in some patients. Symptomatic treatment options span multiple domains: fatigue (pyridostigmine bromide, antidepressants, methylphenidate, amantadine, modafinil; energy conservation, work modification, sleep study with BiPAP if abnormal), spasticity (baclofen, tizanidine, dantrolene sodium, diazepam; physical therapy, range-of-motion exercises, botulinum toxin), jaw clenching (benzodiazepines, botulinum toxin into masseters), cramps (quinine sulfate, baclofen, vitamin E, clonazepam; massage, physical therapy), fasciculations (carbamazepine and reassurance), sialorrhea (hyoscyamine sulfate, diphenhydramine, scopolamine patch, glycopyrrolate, atropine, TCAs; suction machine, botulinum toxin into salivary glands, parotid radiation therapy, steam inhalation, nebulization, dark grape juice), pseudobulbar laughing/crying (TCAs, SSRIs, L-dopa/carbidopa, lithium, mirtazapine, venlafaxine, quinidine/dextromethorphan), thick phlegm (guaifenesin, nebulized N-acetylcysteine, nebulized saline, propranolol; insufflation-exsufflation, high-flow chest wall oscillation therapy, cool mist humidifier, rehydration, pineapple/papaya juice, reduced dairy/caffeine/alcohol), aspiration (cisapride and modified food consistency; in severe cases tracheostomy or modified laryngectomy with tracheal diversion), joint pains (anti-inflammatory drugs, analgesics, range-of-motion and heat), depression (TCAs; SSRIs/venlafaxine/mirtazapine/bupropion; counseling, support groups, psychiatry), insomnia (zolpidem tartrate, lorazepam, opioids, TCAs; pressure air pad/gel mattress; noninvasive ventilation where appropriate), laryngospasm (sublingual lorazepam), respiratory failure (bronchodilators, morphine sulfate; hospital bed, nocturnal noninvasive ventilator, IPPB), and constipation (increase oral fluids, Metamucil, Dulcolax suppositories, lactulose/other laxatives, exercise, “power pudding” of prune juice/prunes/applesauce/bran).
Nonpharmacologic therapy is central. Noninvasive ventilation can improve quality of life and may increase tracheostomy-free survival in patients with respiratory difficulty (orthopnea or FVC ≤50% predicted). Percutaneous endoscopic gastrostomy (PEG) can improve nutrition, stabilize weight, and ease medication administration; some studies suggest it may prolong life by 1–4 months, especially when placed before FVC falls to ≤50% predicted. Supportive services include nutrition support, speech therapy, physical and occupational therapy, suction devices for sialorrhea, cough assist devices for ineffective cough and airway clearance, and computerized assistive communication devices. Early advance-care planning discussions should address living will, resuscitation orders, preferences regarding PEG and tracheostomy, and long-term care options, and patients should be encouraged to connect with local support groups.
Disease-modifying medications do not cure ALS but can slow progression in selected patients. Riluzole (glutamate antagonist) was the first FDA-approved medication shown to extend tracheostomy-free survival; typical dosing is 50 mg every 12 hours, taken at least 1 hour before or 2 hours after meals, and it prolongs survival by about 2–3 months; ALT monitoring is recommended monthly for the first 3 months, then every 3 months until completion of the first year, and periodically thereafter. Edaravone (FDA approved 2017) slowed physical decline by 33% versus placebo in a 6-month phase III trial; it is given IV with an initial cycle of daily infusions for 14 days followed by 14 days off, then subsequent cycles of 10 infusions over 14 days followed by 14 days off; cost and insurance coverage can be limiting. Relyvrio (sodium phenylbutyrate/taurursodiol) is an FDA-approved oral fixed-dose combination (approved 2022) for adults with ALS that helps slow progression; its exact mechanism is unknown, but it targets endoplasmic reticulum and mitochondria-dependent neuronal degeneration pathways, and is thought to reduce neuronal death and dysfunction.
Chronic management includes targeted symptom control such as treating sialorrhea with glycopyrrolate or amitriptyline (and considering propranolol or metoprolol if secretions are thick), using botulinum toxin if refractory; treating spasticity with baclofen, tizanidine, or clonazepam; and treating pseudobulbar affect with amitriptyline, sertraline, or dextromethorphan/quinine.
Disposition reflects the progressive nature of ALS: there is currently no cure, mean symptom duration is 3-5 years, and about 20% of patients survive more than 5 years. Referral to a neurologist experienced in neuromuscular disease is recommended to confirm diagnosis, and multidisciplinary ALS clinics may improve survival. Gastroenterology referral for PEG placement is recommended while FVC remains >50% to reduce procedural morbidity, and pulmonology referral is appropriate for noninvasive ventilation such as BiPAP.
Pearls include the importance of patient-physician communication at diagnosis and throughout care, and the value of a multidisciplinary supportive approach to improve daily functioning and independence. Related content includes patient information resources on ALS.
- Published on
KembaraXtra-Medicine – Amphetamine Use Disorder
Amphetamine use disorder is a pattern of amphetamine use marked by impairment in control of use or social obligations, risky use, or physical dependence within a 12-month period. Severity is categorized as mild, moderate, or severe based on the number of symptoms. Amphetamines are central nervous system stimulants that increase monoamine neurotransmitters (dopamine, norepinephrine, serotonin) and are defined by a phenylethylamine structure. Amphetamine and dextroamphetamine are FDA approved for AD/HD, narcolepsy, and obesity. Methamphetamine is a type of amphetamine that is FDA approved for AD/HD and obesity, but is more commonly illicitly produced and used recreationally. Synonyms include stimulant use disorder and methamphetamine use disorder. ICD-10CM codes include F15.10 (mild), F15.20 (moderate or severe), F15.11 (mild, in early or sustained remission), and F15.21 (moderate or severe, in early or sustained remission).
Epidemiologically, prevalence is described as rare: 0.6% among people ages ≥12 years (about 1.5 million) with methamphetamine use disorder, and 0.3% among people ≥12 years (about 758,000) with prescription stimulant use disorder. Among adults who used methamphetamine in the past year, 53% met criteria for methamphetamine use disorder. Methamphetamine use disorder is more common among those age 26 and older (0.6%) than under age 25, while prescription stimulant use disorder is more common between ages 12 and 25 compared with ≥26.
Risk increases in people with any substance use disorder. Among psychiatric comorbidities, bipolar disorder, schizophrenia, and antisocial personality disorder are associated with stimulant use disorder. Demographic risk factors for methamphetamine use include male sex, lower educational attainment, and non-Hispanic White ethnicity. Methamphetamine use is higher among men who have sex with men, including in “chemsex,” where methamphetamine and other stimulants are used to increase arousal and reduce inhibition during sexual sessions.
Clinically, amphetamine use disorder can develop as quickly as within 1 week of exposure, and most people experience physical dependence in the form of tolerance or withdrawal. Amphetamines may be used by oral ingestion, insufflation, injection, or smoking, and use is often described as chronic or episodic binges. During intoxication, patients may report euphoria and may present with hyperarousal, aggressive behavior, psychosis (paranoia and hallucinations), panic attacks, or suicidal and homicidal ideation. With toxicity, sympathomimetic signs such as hypertension, tachycardia, dilated pupils, and flushed skin can occur. Some intoxicated patients report chest pain, and amphetamine use increases risk of myocardial infarction, arrhythmias, and strokes. During withdrawal, patients commonly report depressive symptoms. Risk for psychosis increases with higher frequency and amount of use, and psychosis can occur within months to several years after starting amphetamine use.
The exact cause of amphetamine use disorder is not known, but amphetamine-type medications act on the dopamine and monoamine transporter (DAT and VMAT2), increasing dopamine transmission in the mesolimbic dopamine pathway (the reward pathway).
In diagnosis, amphetamine use disorder is different from amphetamine misuse, which refers to use inconsistent with prescription guidelines. Patients using PCP or novel psychoactive substances (such as cathinones/bath salts) may present similarly and can be distinguished with a toxicology test. Primary psychiatric disorders (e.g., schizophrenia) or depressive disorders (e.g., major depressive disorder) can be evaluated by establishing a timeline of symptoms relative to amphetamine use; psychosis that quickly improves is more consistent with amphetamine-induced psychosis.
Work-up may be difficult because detailed history can be hard to obtain during acute intoxication or withdrawal. An ECG should be performed in patients with tachycardia. A safety assessment is essential to determine whether the patient can safely care for themselves, especially when suicidal or homicidal ideation is reported. Recommended labs include basic testing such as Chem 7, serum lactate, creatine phosphokinase, thyroid function tests, and hepatic enzymes. A urine or serum toxicology test can confirm amphetamine presence. There are no radiographic tests for diagnosis of stimulant use disorder, but CT imaging may be considered for strokes or vasculopathies associated with amphetamine use.
Treatment is primarily nonpharmacologic, with behavioral interventions as the mainstay. Approaches such as contingency management, cognitive-behavioral therapy, behavioral activation, and exercise have shown mild effectiveness in reducing symptoms and sustaining abstinence. Contingency management, especially when combined with community reinforcement (reorganizing the environment so abstinence is more rewarding than drug use), has been particularly shown to be effective.
For acute general management, antipsychotics—especially olanzapine and haloperidol—have evidence for treating amphetamine-associated psychosis. No medication has been shown to be effective for amphetamine withdrawal. There is limited evidence that amineptine (a tricyclic antidepressant no longer available due to abuse potential) reduced discontinuation symptoms and improved clinical presentation, and there is mixed evidence that mirtazapine may reduce anxiety symptoms during withdrawal.
For chronic management, there is no evidence that pharmacologic treatment alone is sufficient. Randomized controlled trials show limited benefit from methylphenidate, bupropion, modafinil, and naltrexone in reducing amphetamine use.
Disposition-wise, methamphetamine use disorder often follows a course of intense use, sobriety, and relapse. Complications of amphetamine intoxication (including ecstasy) include hyponatremia due to SIADH (very rare; managed with water restriction), intracerebral hemorrhage (uncommon; CT/MRI if focal signs or reduced GCS), serotonin toxicity (uncommon; supportive care and cyproheptadine for serious cases), hypertension (uncommon; GTN infusion, benzodiazepines, labetalol; avoid beta-blockers), hyperthermia (common; cooling measures, diazepam, cyproheptadine), rhabdomyolysis (uncommon; IV fluids and cooling), supraventricular and ventricular tachycardia (uncommon; short-acting antiarrhythmics such as esmolol for SVT), and seizures (uncommon; IV diazepam).
Referral is typically to physicians and mental health professionals. Important pearls include that stimulant use disorders often co-occur with sedative substance use disorders (e.g., alcohol, marijuana, opioids) because these may relieve stimulant side effects such as insomnia and anxiety. Amphetamine use is also associated with an increased risk of death by suicide, so assessing suicidality is critical in any patient presenting with amphetamine use.
For prevention, community-based universal prevention programs that promote youth social-emotional skills and reduce risk factors have been shown to lead to sustained reductions in lifetime methamphetamine use.
- Published on
KembaraXtra-Medicine – Amyloidosis
Amyloid is an altered, insoluble protein folded in β-pleated sheets that is deposited extracellularly. Amyloid can accumulate in one or many organs, causing organ dysfunction. Amyloidosis refers to a heterogeneous group of disorders characterized by deposition of an amorphous, extracellular fibrillar protein in various organs and tissues. Subtypes include primary amyloidosis (AL), secondary amyloidosis (AA), hereditary amyloidosis, and localized amyloidosis. ICD-10CM codes include E85.0 (non-neuropathic heredofamilial), E85.1 (neuropathic heredofamilial), E85.2 (heredofamilial, unspecified), E85.3 (secondary systemic), E85.4 (organ-limited), E85.8 (other), and E85.9 (unspecified).
Amyloidosis nomenclature is based on the amyloid protein precursor and associated clinical features. AL or AH derives from immunoglobulin light or heavy chain and is primary or localized, often associated with myeloma or macroglobulinemia. AA derives from serum amyloid A (SAA) and occurs as secondary amyloidosis or with familial Mediterranean fever and other familial periodic fever syndromes. ATTR derives from transthyretin and is familial or senile. A fibrinogen derives from fibrinogen and is associated with familial renal amyloidosis (Ostertag type). Aβ2M derives from β2-microglobulin and is dialysis-associated, including carpal tunnel syndrome. Aβ derives from amyloid-β precursor protein (ABPP) and is associated with Alzheimer disease. Apo A-I/A-II–related forms include apolipoprotein A-I (proteinuria) and apolipoprotein A-II (cardiac and neuropathy patterns). A lysozyme involves lysozyme deposition affecting the GI tract, liver, and kidneys. ALECT2 is noted as a renal form (leukocyte chemotactic factor 2 amyloidosis).
A major classification system (not exhaustive) includes: AA (serum amyloid A) causing systemic amyloidosis, often predominantly renal, linked to acquired or hereditary chronic inflammatory disease (formerly “secondary/reactive”); AL (monoclonal immunoglobulin light chains) causing systemic amyloidosis potentially involving many organs and associated with myeloma/monoclonal gammopathy/occult B-cell dyscrasias (formerly “primary”); and ATTR wild-type (normal plasma transthyretin) causing nonhereditary systemic amyloidosis with predominantly cardiac involvement (formerly “senile cardiac amyloidosis”). ATTR variant (genetic variants such as ATTR Met30, Ala60, Ile122) can cause familial amyloid polyneuropathy (FAP) often with prominent cardiomyopathy, and certain mutations (e.g., TTR Ile122) may produce predominantly cardiac involvement without neuropathy. Aβ2M (β2-microglobulin) causes dialysis-related amyloidosis with renal failure and long-term dialysis, with predominantly articular/periarticular involvement. Aβ causes cerebrovascular and intracerebral plaque amyloid in Alzheimer disease and may be familial. AApoAI (genetic variants of apolipoprotein AI) causes autosomal dominant systemic amyloidosis, typically nonneuropathic with visceral involvement—especially nephropathy—and minor wild-type deposits can occur in the aorta with aging. AApoAII causes autosomal dominant systemic amyloidosis with predominantly renal involvement. AFib (fibrinogen A α-chain variants) causes autosomal dominant systemic amyloidosis with nonneuropathic predominant nephropathy. ALys (lysozyme variants) causes autosomal dominant systemic amyloidosis with predominantly renal and GI involvement and can rarely present with hepatic rupture. ACys (cystatin C variant) is linked to hereditary cerebral hemorrhage with cerebral and systemic amyloidosis in Icelandic individuals. AGel (gelsolin variants) causes autosomal dominant systemic amyloidosis with predominantly cranial nerve involvement plus lattice corneal dystrophy and is described as most common in Finland.
In the United States, incidence is estimated at 1500–3500 new cases annually, with AL being the most common type. Amyloidosis primarily affects men ages 60–70 years. Common presenting symptoms include fatigue, dyspnea, edema, paresthesias, and weight loss, and other findings depend on organ involvement. Diagnosis should be considered in patients with a multisystem disorder involving the heart, kidney, liver, or nervous system. Renal involvement may present with nephrotic syndrome. Pulmonary involvement may cause fatigue and dyspnea. GI involvement is uncommon but may present with diarrhea, nausea, abdominal pain, and macroglossia. Cardiac involvement produces an infiltrative cardiomyopathy with preserved ejection fraction and diastolic dysfunction; in transthyretin-related disease, transthyretin dissociation leads to deposition of misfolded monomers as amyloid fibrils in the myocardium with subsequent cardiomyopathy and heart failure. Patients may have bleeding problems from factor X deficiency or fragile vessels infiltrated by amyloid; periorbital bleeding (“raccoon eyes”) is characteristic. Nervous system involvement can cause peripheral neuropathy, tendinopathy, muscle weakness, numbness, syncope, or dizziness, and associated autonomic neuropathy can be severely disabling. Syndromes in primary (AL) amyloidosis include nephrotic/nephrotic with renal failure (30%), hepatomegaly (24%), congestive heart failure (22%), carpal tunnel (21%), neuropathy (17%), and orthostatic hypotension (12%).
The common mechanism is deposition of Congo red–staining amyloid fibrils, but key subtype differences exist. AL is associated with an underlying clonal plasma cell disorder producing abnormal light chains with possible multi-organ deposition. AA has no plasma cell disorder and results from long-standing systemic inflammation (examples listed include tuberculosis, leprosy, malaria, untreated syphilis). Localized amyloidosis results from localized fibril synthesis without a plasma cell disorder. Familial amyloidosis includes forms due to transthyretin gene (TTR) mutations, with hepatocyte-derived transthyretin deposition in peripheral nerves and the heart.
Differential diagnosis depends on organ involvement. For renal disease consider toxin- or drug-induced necrosis, glomerulonephritis, renal vein thrombosis. For pulmonary disease consider sarcoidosis, connective tissue disease, infectious causes. For restrictive cardiomyopathy consider endomyocardial fibrosis or viral myocarditis. For carpal tunnel consider rheumatoid arthritis, hypothyroidism, overuse. For peripheral neuropathy consider alcohol abuse, vitamin deficiencies, diabetes mellitus.
Workup includes blood and urine testing for abnormal light chains, tests for target-organ damage, and histologic confirmation. Typical confirmation is via fat pad aspiration and bone marrow biopsy with Congo red staining. Recommended diagnostic evaluation includes CBC; chemistries and other labs (sodium, potassium, alkaline phosphatase, calcium, phosphorus, AST, bilirubin, creatinine, β2-microglobulin, glucose, cholesterol, uric acid, thyroid profile); serum and urine immunofixation; assays for immunoglobulin free light chains and immunoglobulins G, A, and M; cardiac markers (troponin, NT-proBNP); coagulation evaluation (factor X and prothrombin time); and cardiac/pulmonary assessment with chest x-ray, ECG, and echocardiogram with Doppler and strain imaging. Amyloid staging assigns 1 point each for FLC-diff ≥18 mg/dL, cTnT ≥0.025 ng/mL, and NT-proBNP ≥1800 pg/mL, producing stages I–IV (scores 0–3). Reported median survival (months) by stage is 94.1, 40.3, 14, and 5.8, respectively. Laboratory testing also includes SPEP/UPEP with immunofixation for light chains, routine labs such as BUN/creatinine, liver function tests, thyroid function, urine albumin, and biopsy confirmation; if fat pad biopsy is negative, biopsy of the affected organ may be required.
Imaging can help define organ involvement. Cardiac MRI may show a distinctive pattern. Two-dimensional Doppler echocardiography is useful for cardiac evaluation but is less sensitive than cardiac MRI. Nuclear imaging with technetium-labeled aprotinin may detect cardiac amyloidosis. Labeled diphosphonates are important for typing amyloidosis and diagnosing heart involvement in transthyretin cardiac amyloidosis, and bone scintigraphy may detect cardiac involvement earlier than echocardiography in transthyretin patients. Serum amyloid P (SAP) scintigraphy has high sensitivity for detecting deposits in liver, spleen, kidneys, adrenal glands, bones.
Acute/general management and disease-directed therapy depend on subtype and organ involvement. Patients with AL amyloidosis should be evaluated for autologous hematopoietic stem cell transplantation (HSCT); good candidates include those with good performance status, age <70, and limited organ involvement. tafamidis is an oral transthyretin stabilizer fda approved for adults with transthyretin-mediated amyloid cardiomyopathy (attr-cm) has been shown to decrease hospitalizations deaths in attr-cm. al, chemotherapy aims reduce production of amyloidogenic light chains by targeting clonal plasma cells; agents used multiple myeloma are effective, including melphalan prednisone, imids (thalidomide, lenalidomide) proteasome inhibitors also used. patients ineligible autologous hsct should receive melphalan- or bortezomib-based regimens. trials oligonucleotide drugs (inotersen, patisiran) have improvement clinical manifestations hereditary amyloidosis. who develop renal failure may require hemodialysis transplant. liver transplantation successfully familial secondary (aa) amyloidosis, recognition treatment the underlying disorder needed. newly diagnosed al show that adding daratumumab bortezomib, cyclophosphamide, dexamethasone associated higher hematologic complete response rates.< />pan>
Major treatment options include, for AL amyloidosis, IV melphalan with autologous stem cell rescue (G-CSF mobilized peripheral blood stem cell collection, IV melphalan 140–200 mg/m², autologous stem cell reinfusion), cyclic oral melphalan and dexamethasone (melphalan 0.22 mg/kg/day ×4 days; dexamethasone 20–40 mg/day ×4 days or weekly; repeat every 4 weeks), immunomodulators (lenalidomide 5–15 mg/day ×21 days with dexamethasone 20–40 mg weekly; repeat every 4 weeks), and proteasome inhibitors (IV bortezomib 0.7–1.6 mg/m² 1–2 times per week; repeat every 3–5 weeks). For AA amyloidosis, options include aggressive treatment of underlying inflammatory disease, medical or surgical treatment of infection, colchicine 1.2–1.8 mg/day for AA secondary to familial Mediterranean fever, and investigational antifibril drug eprodisate. For ATTR, options include orthotopic liver transplantation, transthyretin stabilizers (tafamidis, investigational diflunisal), and investigational oligonucleotide drugs (inotersen, patisiran).
Supportive treatment across all amyloidosis types is symptom- and organ-directed. For cardiac congestive failure, options include salt restriction 1–2 g/day and diuretics (furosemide, spironolactone, metolazone). For arrhythmias, consider pacemaker, automatic implantable cardiac defibrillator, and antiarrhythmics. For renal nephrotic syndrome, use salt restriction 1–2 g/day, elastic stockings and leg elevation, maintaining dietary protein, and an ACE inhibitor if blood pressure tolerates. For renal failure, use dialysis (long-term ambulatory peritoneal dialysis or hemodialysis). For autonomic nervous system orthostatic hypotension, options include midodrine, increased dietary salt or fludrocortisone depending on edema, and elastic stockings. For gastric atony/ileus, use small frequent low-fat feedings (6/day), oral nutritional supplements, jejunostomy tube feeding, or parenteral nutrition. For GI diarrhea, options include a low-fat diet (≤40 g), psyllium, loperamide, tincture of opium, and parenteral nutrition. For macroglossia, use a soft solid diet; partial glossectomy is rarely effective. For peripheral sensory neuropathy, avoid trauma and use medications such as gabapentin 100–300 mg three times daily, amitriptyline 25–50 mg at bedtime, or pregabalin 50–100 mg three times daily. For motor neuropathy with footdrop, use ankle-foot orthotics and physical therapy. For hematologic issues with intracutaneous bleeding, avoid trauma and antiplatelet agents; for factor X deficiency, use factor replacement (recombinant factor VIIa, prothrombin complex concentrates). Splenectomy may be considered for splenomegaly.
Prognosis is determined primarily by cardiac involvement and the amyloidosis form. In endomyocardial biopsy–documented cardiac amyloidosis, longer-term survival correlates more strongly with NYHA functional class than with ECG or echocardiographic variables. In AA amyloidosis, eradication of the predisposing disease slows and can occasionally reverse progression, with a median survival after diagnosis of 133 months. Patients with familial amyloidotic polyneuropathy often have a prolonged course of 10–15 years. Dialysis-associated amyloidosis progression can be improved with newer dialysis membranes that pass β2-microglobulin. Median survival in patients with overt congestive heart failure is approximately 6 months, compared with 30 months without CHF.
- Published on
KembaraXtra-Medicine – Amblyopia
Amblyopia refers to decreased vision in one or both eyes resulting from insufficient stimulation of the developing visual system during childhood. It occurs when normal visual development is disrupted, leading to reduced visual acuity that cannot be fully corrected with glasses alone. The most common causes are ocular misalignment (strabismus) and unequal refractive error between the eyes (anisometropia). Less commonly, amblyopia develops due to bilateral high refractive error (ametropic amblyopia) or visual deprivation, in which the ocular media are obstructed by conditions such as congenital cataract or severe ptosis.
Amblyopia is also known by several synonyms, including lazy eye, strabismic amblyopia, refractive amblyopia, occlusion amblyopia, and deprivation amblyopia (formerly called amblyopia ex anopsia). The condition is classified under multiple ICD-10CM codes, including unspecified amblyopia (H53.009), deprivation amblyopia (H53.01x), refractive amblyopia (H53.02x), and strabismic amblyopia (H53.03x), with laterality and bilaterality specified where applicable.
From an epidemiologic standpoint, amblyopia affects approximately 1% to 5% of the general population in the United States and represents the most common cause of decreased vision in children. It is responsible for permanent vision impairment in about 2.9% of adults. The condition is more common in premature infants, especially those born to drug-dependent mothers, and in neurologically impaired children. Additional risk factors include a family history of amblyopia, strabismus, or high refractive errors. There is no sex predilection, and the condition typically presents in early childhood, which is also the period of peak incidence.
The clinical presentation of amblyopia most often consists of reduced visual acuity in one eye despite appropriate corrective lenses, while the eye otherwise appears healthy on examination. In some cases, decreased vision may be associated with visible ocular abnormalities, such as a congenital cataract. Children may demonstrate a fixation preference, resisting occlusion of the better-seeing eye while tolerating coverage of the amblyopic eye, which is an important clinical clue.
The etiology of amblyopia includes refractive errors, strabismus, and visual deprivation caused by congenital cataract, corneal opacities, ptosis, or nystagmus. Rarely, amblyopia may result from prolonged occlusion due to patching or from systemic factors such as malnutrition or vitamin deficiency.
Diagnosis is best established through careful monocular visual acuity testing at the earliest possible age, generally around 3 years old. In preverbal or nonverbal children, photoscreening can help identify amblyopia or associated risk factors. Photoscreeners are increasingly available in primary care settings; however, clinicians should be aware that false-positive results are common, and abnormal findings require confirmation.
The differential diagnosis includes central nervous system causes such as cortical visual impairment, optic nerve disorders, corneal disease, retinal disorders, and, less commonly, malingering or secondary gain, such as a desire for glasses, which is reported more frequently in children, particularly girls.
The workup involves a complete eye examination to determine the underlying cause of reduced vision. Referral to an ophthalmologist is recommended for any child with visual acuity of 20/40 or worse in either eye, a two-line difference in visual acuity between the eyes, or failure of a photoscreening test in preverbal or nonverbal children. An ocular motility examination is essential to assess for strabismus. Laboratory testing is usually unnecessary, and imaging studies are generally not required unless a central nervous system abnormality is suspected.
Treatment depends on the age of the patient and the underlying etiology. Corrective glasses are used to address significant refractive errors and may help align the eyes in certain forms of strabismus. Penalization of the better-seeing eye, either by patching or atropine 1% eye drops, is the cornerstone of amblyopia therapy. The duration of treatment typically spans months and varies according to patient age, treatment response, and compliance. Younger children, especially those under 5 years of age, tend to respond more rapidly and completely, although some older children over 10 years of age who have never been treated may still show improvement.
Emerging therapies include digital or virtual reality–based dichoptic treatments, which aim to selectively stimulate the amblyopic eye. Although these technologies are under development and beginning to enter clinical use, there is no clear evidence that they are superior to traditional treatments, and they are often significantly more expensive. Surgical intervention is indicated in cases of deprivation amblyopia caused by conditions such as congenital cataract or severe congenital ptosis.
For chronic management, maintenance therapy with glasses, patching, or atropine may be required until the child reaches visual maturity, which typically occurs around 9 to 10 years of age. Continued monitoring during this period is essential to detect and prevent relapse.
Referral to an ophthalmologist is indicated whenever vision is compromised or amblyopia is suspected. Early specialist involvement improves diagnostic accuracy and treatment outcomes.
Important clinical pearls include the fact that earlier diagnosis leads to better outcomes, with the most robust treatment responses seen in children younger than 5 years. Nevertheless, treatment can still be beneficial in selected older children. Compliance with therapy is the single most important determinant of success. Recurrence is relatively common, with amblyopia returning in approximately 25% of children after patching is discontinued, underscoring the need for long-term follow-up.
